Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ariad Pharmaceuticals Inc.

Division of Takeda Pharmaceutical Co. Ltd.
www.ariad.com

Latest From Ariad Pharmaceuticals Inc.

Latecomer Alunbrig Faces Entrenched Rivals After US 1L Approval

First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.

United States Approvals

Takeda’s Alunbrig To Battle Entrenched EU Competitors In First-Line ALK-Positive NSCLC

EU Approvals: Takeda advances its targeted ALK-positive NSCLC tyrosine kinase inhibitor into early lines of therapy, while Bayer and Finland’s Orion gain clearance for their androgen receptor inhibitor for prostate cancer.

Approvals Europe

Hypera Pays $825m For Takeda LatAm Portfolio

Major new portfolio divestment, along with Deerfield site sale, form part of ongoing effort to pay down Shire-related debt and focus on novel drugs.

South America Business Strategies

Japan 2010s In Review: Specialize, Focus, Innovate

Reimbursement issues continued to dominate the policy sphere in Japan during the last decade, while new forms of therapy benefited from positive regulatory reforms. Meanwhile, consolidation and specialization were major threads running through the corporate sector.

Japan Reimbursement
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Takeda Pharmaceutical Co. Ltd.
  • Senior Management
  • Paris Panayiotopoulos, Pres. & CEO
    Jennifer L Herron, EVP, Chief Commercial Officer
    Hugh M Cole, SVP & CBO
  • Contact Info
  • Ariad Pharmaceuticals Inc.
    Phone: (617) 494-0400
    26 Landsdowne St.
    Cambridge, MA 02139-4234
    USA
UsernamePublicRestriction

Register